RxDoctor Payments Data

Rodney Fair, OD

Optometrist · Brighton, CONPI 1568455400

Payments from drug & device makers

$1,478in general payments, 2019–2025

Across 46 payments — averaging $32.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$294
  • Sun Pharmaceutical Industries Inc.$188
  • Glaukos Corporation$151
  • Ocular Therapeutix, Inc.$150
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$135
  • Hoffmann-la Roche Limited$134
  • plus $426 from 10 others

What the payments were for

  • Travel & lodging$91%
  • Food & beverage$1,44998%
  • Entertainment$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,478 in reported general payments places this provider in the 70th percentile of 1,025 optometrist providers in Colorado.

See all optometrist providers in Colorado

Medicare billing

Part B allowed, 2024
$45,561
Medicare patients
213
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine150$124,100
TyrvayaVarenicline Tartrate49$34,907
LumiganBimatoprost36$16,004
Cyclosporine33$14,499
CequaCyclosporine13$12,456
XiidraLifitegrast13$12,103
RocklatanNetarsudil Mesylat/Latanoprost24$10,570
CombiganBrimonidine Tartrate/Timolol14$3,756
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$2,976
SimbrinzaBrinzolamide/Brimonidine Tart12$2,832
Travoprost22$2,325
Fluorometholone25$1,807
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,407
Latanoprost181$1,249
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat79$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$29$143,860200 claims
Oyster Point Pharma, Inc.Tyrvaya$100$34,90749 claims
Sun Pharmaceutical Industries Inc.Cequa$188$12,45613 claims
AlconSimbrinza$294$2,83212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,025 optometrist providers in Colorado.

Other optometrist in Brighton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →